Abbvie Inc Common Stock (ABBV) 64.61 $ABBV AbbV
Post# of 273249
Posted On: 09/07/2016 7:00:57 AM
Abbvie Inc Common Stock (ABBV) 64.61 $ABBV
AbbVie to Present at the Morgan Stanley Global Healthcare Conference
PR Newswire - Tue Aug 30, 7:00AM CDT
AbbVie (NYSE: ABBV) will participate in the Morgan Stanley Global Healthcare Conference on Wednesday, Sept. 14, 2016. Bill Chase, executive vice president and chief financial officer, will participate in a question and answer session at 10:40 a.m. Central time.
ABBV: 64.61 (+0.49), MS: 31.75 (-0.14)
Zacks Value Investor Highlights: AbbVie, Berry Plastics, Hawaiian Holdings, Toll Brothers and Pulte
Zacks Equity Research - Zacks Investment Research - Fri Aug 19, 8:30AM CDT
Zacks Value Investor Highlights: AbbVie, Berry Plastics, Hawaiian Holdings, Toll Brothers and Pulte
BERY: 45.62 (-0.35), HA: 48.01 (+0.41), PHM: 20.84 (-0.04), ABBV: 64.61 (+0.49), TOL: 30.97 (+0.25)
How Value Investors Can Buy Growth
Tracey Ryniec - Zacks Investment Research - Wed Aug 17, 5:03PM CDT
Value and growth is a magical combination. Here???s how to get it.
BERY: 45.62 (-0.35), HA: 48.01 (+0.41), PHM: 20.84 (-0.04), ABBV: 64.61 (+0.49), TOL: 30.97 (+0.25)
J&J's (JNJ) Depression Treatment Esketamine Gets BTD
Arpita Dutt - Zacks Investment Research - Wed Aug 17, 5:50AM CDT
FDA granted Breakthrough Therapy Designation (BTD) to J&J's (JNJ) esketamine for major depressive disorder with imminent risk for suicide.
JNJ: 119.75 (+0.43), GERN: 3.02 (+0.27), ABBV: 64.61 (+0.49)
The Zacks Analyst Blog Highlights: Regeneron, BioMarin, AbbVie, Amgen and Biogen
Zacks Equity Research - Zacks Investment Research - Fri Aug 12, 8:30AM CDT
The Zacks Analyst Blog Highlights: Regeneron, BioMarin, AbbVie, Amgen and Biogen
BIIB: 310.67 (-2.92), BMRN: 95.59 (-0.14), AMGN: 170.84 (+1.07), ABBV: 64.61 (+0.49), REGN: 398.31 (+9.67)
Biotech Stock Roundup: Earnings in Focus, AbbVie Takes Steps to Block Humira Copycat
Arpita Dutt - Zacks Investment Research - Thu Aug 11, 4:30PM CDT
Earnings remained in focus with several companies including Regeneron (REGN) reporting second quarter results.
MDVN: 80.84 (-0.01), BIIB: 310.67 (-2.92), BMRN: 95.59 (-0.14), AMGN: 170.84 (+1.07), ABBV: 64.61 (+0.49), MNTA: 12.23 (-0.07), REGN: 398.31 (+9.67)
Major Drug Makers Stocks Under Review -- Pfizer, AbbVie, Merck, and Johnson & Johnson
PR Newswire - Tue Aug 09, 8:17AM CDT
With the U.S. election fast approaching, some investors cannot help but question the outcome's probable impact on the Healthcare sector. A post-election scenario may lead to potential drug-price reductions and amended policies. This morning, Stock-Callers.com issued research reports on four major companies in the Drug Manufacturers industry, namely: Pfizer Inc. (NYSE: PFE), AbbVie Inc. (NYSE: ABBV), Merck & Co. Inc. (NYSE: MRK), and Johnson & Johnson (NYSE: JNJ). Learn more about these stocks by downloading their free research reports in PDF format at:
JNJ: 119.75 (+0.43), MRK: 63.24 (+0.26), PFE: 34.77 (unch), ABBV: 64.61 (+0.49)
4 Biotech Stocks Poised to Surprise This Earnings Season
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 3:18PM CDT
Notwithstanding the sector declines, things appear far better now than they did a quarter ago for the biotech sector.
BIIB: 310.67 (-2.92), BMRN: 95.59 (-0.14), GILD: 77.88 (+0.99), AMGN: 170.84 (+1.07), ABBV: 64.61 (+0.49), ARIA: 10.41 (+0.29), AEGN: 19.11 (+0.10)
Top Research Reports for Morgan Stanely, Union Pacific & AbbVie
Sheraz Mian - Zacks Investment Research - Mon Aug 01, 2:21PM CDT
Top Research Reports for Morgan Stanely, Union Pacific & AbbVie
KO: 43.79 (+0.13), MCK: 184.69 (+1.71), NWL: 54.04 (+0.47), ABBV: 64.61 (+0.49), APD: 157.40 (+0.31), UNP: 95.97 (+0.69), MS: 31.75 (-0.14)
Company News for August 01, 2016
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 9:10AM CDT
Companies in the News are: XRX,MRK,ABBV,EXPE
MRK: 63.24 (+0.26), EXPE: 113.91 (+1.86), ABBV: 64.61 (+0.49), XRX: 9.80 (-0.09)
What Awaits MNK & Other Drug Stocks this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 9:00AM CDT
Let's see what's in store for some medical companies that are expected to declare quarterly numbers on Aug 2.
MNK: 74.92 (+2.50), BIIB: 310.67 (-2.92), ABT: 42.16 (+0.07), JNJ: 119.75 (+0.43), GILD: 77.88 (+0.99), MRK: 63.24 (+0.26), PFE: 34.77 (unch), SGNT: 21.76 (+0.03), ABBV: 64.61 (+0.49), PRTA: 54.51 (+2.32), NVS: 80.15 (+0.77)
AbbVie (ABBV) Beats on 2Q Earnings, Revenues, Ups View
Arpita Dutt - Zacks Investment Research - Fri Jul 29, 9:44AM CDT
AbbVie (ABBV) raised its 2016 outlook following its Q2 earnings and revenue beat.
JNJ: 119.75 (+0.43), ABBV: 64.61 (+0.49), LLY: 78.51 (+1.66), BMY: 56.96 (+0.61)
Q2 GDP Disappoints, Q2 Earnings Mixed Ahead of Bell: XOM, CVX, UPS, ABBV, BCS
Mark Vickery - Zacks Investment Research - Fri Jul 29, 8:55AM CDT
Both GDP results and Exxon's (XOM) earnings for Q2 were below expectations. Who outperformed the consensus before the bell Friday?
BCS: 9.13 (-0.18), XOM: 88.57 (+1.15), ABBV: 64.61 (+0.49), CVX: 102.43 (+1.50), UPS: 109.50 (-0.09)
AbbVie (ABBV) Tops 2Q Earnings & Revenue Estimates
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 7:58AM CDT
AbbVie (ABBV) surpassed expectations in Q2 and raised its outlook for the year.
ABBV: 64.61 (+0.49)
AbbVie Reports Second-Quarter 2016 Financial Results
PR Newswire - Fri Jul 29, 6:38AM CDT
AbbVie (NYSE:ABBV) announced financial results for the second quarter ended June 30, 2016.
ABBV: 64.61 (+0.49)
AbbVie Announces Initiation of Phase 3 Study of Venetoclax in Patients with Relapsed or Refractory Multiple Myeloma
PR Newswire - Thu Jul 28, 4:30PM CDT
AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced the initiation of a Phase 3 clinical trial to study the safety and efficacy of venetoclax in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma who are considered sensitive or naïve to proteasome inhibitors and have received one to three prior lines of therapy. The combination of venetoclax, bortezomib and dexamethasone will be compared to treatment with bortezomib, dexamethasone and placebo.1 Bortezomib, a proteasome inhibitor, and dexamethasone, a corticosteroid, are both common therapies used to treat symptomatic multiple myeloma.3
ABBV: 64.61 (+0.49)
The Zacks Analyst Blog Highlights: Biogen, Gilead, AbbVie, Amgen and Celgene
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 8:30AM CDT
The Zacks Analyst Blog Highlights: Biogen, Gilead, AbbVie, Amgen and Celgene
BIIB: 310.67 (-2.92), GILD: 77.88 (+0.99), AMGN: 170.84 (+1.07), ABBV: 64.61 (+0.49), CELG: 106.71 (+1.22)
2 Large Cap Drug Stocks to Watch for Earnings: ABBV & MRK
Arpita Dutt - Zacks Investment Research - Thu Jul 28, 5:47AM CDT
Two major large cap drug stocks, AbbVie (ABBV) and Merck (MRK) will be reporting second quarter results tomorrow.
BIIB: 310.67 (-2.92), JNJ: 119.75 (+0.43), GILD: 77.88 (+0.99), MRK: 63.24 (+0.26), AMGN: 170.84 (+1.07), ABBV: 64.61 (+0.49)
Biotech Stock Roundup: Biogen Q2 Results Impress, Gilead HCV Franchise Under Pressure
Arpita Dutt - Zacks Investment Research - Wed Jul 27, 2:25PM CDT
With the second quarter earnings season in full swing, several biotech companies including Amgen (AMGN) will be reporting this week.
BIIB: 310.67 (-2.92), VRTX: 95.78 (+0.67), GILD: 77.88 (+0.99), ALXN: 125.85 (+2.18), AMGN: 170.84 (+1.07), ABBV: 64.61 (+0.49), CELG: 106.71 (+1.22)
AbbVie to Present at the Morgan Stanley Global Healthcare Conference
PR Newswire - Tue Aug 30, 7:00AM CDT
AbbVie (NYSE: ABBV) will participate in the Morgan Stanley Global Healthcare Conference on Wednesday, Sept. 14, 2016. Bill Chase, executive vice president and chief financial officer, will participate in a question and answer session at 10:40 a.m. Central time.
ABBV: 64.61 (+0.49), MS: 31.75 (-0.14)
Zacks Value Investor Highlights: AbbVie, Berry Plastics, Hawaiian Holdings, Toll Brothers and Pulte
Zacks Equity Research - Zacks Investment Research - Fri Aug 19, 8:30AM CDT
Zacks Value Investor Highlights: AbbVie, Berry Plastics, Hawaiian Holdings, Toll Brothers and Pulte
BERY: 45.62 (-0.35), HA: 48.01 (+0.41), PHM: 20.84 (-0.04), ABBV: 64.61 (+0.49), TOL: 30.97 (+0.25)
How Value Investors Can Buy Growth
Tracey Ryniec - Zacks Investment Research - Wed Aug 17, 5:03PM CDT
Value and growth is a magical combination. Here???s how to get it.
BERY: 45.62 (-0.35), HA: 48.01 (+0.41), PHM: 20.84 (-0.04), ABBV: 64.61 (+0.49), TOL: 30.97 (+0.25)
J&J's (JNJ) Depression Treatment Esketamine Gets BTD
Arpita Dutt - Zacks Investment Research - Wed Aug 17, 5:50AM CDT
FDA granted Breakthrough Therapy Designation (BTD) to J&J's (JNJ) esketamine for major depressive disorder with imminent risk for suicide.
JNJ: 119.75 (+0.43), GERN: 3.02 (+0.27), ABBV: 64.61 (+0.49)
The Zacks Analyst Blog Highlights: Regeneron, BioMarin, AbbVie, Amgen and Biogen
Zacks Equity Research - Zacks Investment Research - Fri Aug 12, 8:30AM CDT
The Zacks Analyst Blog Highlights: Regeneron, BioMarin, AbbVie, Amgen and Biogen
BIIB: 310.67 (-2.92), BMRN: 95.59 (-0.14), AMGN: 170.84 (+1.07), ABBV: 64.61 (+0.49), REGN: 398.31 (+9.67)
Biotech Stock Roundup: Earnings in Focus, AbbVie Takes Steps to Block Humira Copycat
Arpita Dutt - Zacks Investment Research - Thu Aug 11, 4:30PM CDT
Earnings remained in focus with several companies including Regeneron (REGN) reporting second quarter results.
MDVN: 80.84 (-0.01), BIIB: 310.67 (-2.92), BMRN: 95.59 (-0.14), AMGN: 170.84 (+1.07), ABBV: 64.61 (+0.49), MNTA: 12.23 (-0.07), REGN: 398.31 (+9.67)
Major Drug Makers Stocks Under Review -- Pfizer, AbbVie, Merck, and Johnson & Johnson
PR Newswire - Tue Aug 09, 8:17AM CDT
With the U.S. election fast approaching, some investors cannot help but question the outcome's probable impact on the Healthcare sector. A post-election scenario may lead to potential drug-price reductions and amended policies. This morning, Stock-Callers.com issued research reports on four major companies in the Drug Manufacturers industry, namely: Pfizer Inc. (NYSE: PFE), AbbVie Inc. (NYSE: ABBV), Merck & Co. Inc. (NYSE: MRK), and Johnson & Johnson (NYSE: JNJ). Learn more about these stocks by downloading their free research reports in PDF format at:
JNJ: 119.75 (+0.43), MRK: 63.24 (+0.26), PFE: 34.77 (unch), ABBV: 64.61 (+0.49)
4 Biotech Stocks Poised to Surprise This Earnings Season
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 3:18PM CDT
Notwithstanding the sector declines, things appear far better now than they did a quarter ago for the biotech sector.
BIIB: 310.67 (-2.92), BMRN: 95.59 (-0.14), GILD: 77.88 (+0.99), AMGN: 170.84 (+1.07), ABBV: 64.61 (+0.49), ARIA: 10.41 (+0.29), AEGN: 19.11 (+0.10)
Top Research Reports for Morgan Stanely, Union Pacific & AbbVie
Sheraz Mian - Zacks Investment Research - Mon Aug 01, 2:21PM CDT
Top Research Reports for Morgan Stanely, Union Pacific & AbbVie
KO: 43.79 (+0.13), MCK: 184.69 (+1.71), NWL: 54.04 (+0.47), ABBV: 64.61 (+0.49), APD: 157.40 (+0.31), UNP: 95.97 (+0.69), MS: 31.75 (-0.14)
Company News for August 01, 2016
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 9:10AM CDT
Companies in the News are: XRX,MRK,ABBV,EXPE
MRK: 63.24 (+0.26), EXPE: 113.91 (+1.86), ABBV: 64.61 (+0.49), XRX: 9.80 (-0.09)
What Awaits MNK & Other Drug Stocks this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 9:00AM CDT
Let's see what's in store for some medical companies that are expected to declare quarterly numbers on Aug 2.
MNK: 74.92 (+2.50), BIIB: 310.67 (-2.92), ABT: 42.16 (+0.07), JNJ: 119.75 (+0.43), GILD: 77.88 (+0.99), MRK: 63.24 (+0.26), PFE: 34.77 (unch), SGNT: 21.76 (+0.03), ABBV: 64.61 (+0.49), PRTA: 54.51 (+2.32), NVS: 80.15 (+0.77)
AbbVie (ABBV) Beats on 2Q Earnings, Revenues, Ups View
Arpita Dutt - Zacks Investment Research - Fri Jul 29, 9:44AM CDT
AbbVie (ABBV) raised its 2016 outlook following its Q2 earnings and revenue beat.
JNJ: 119.75 (+0.43), ABBV: 64.61 (+0.49), LLY: 78.51 (+1.66), BMY: 56.96 (+0.61)
Q2 GDP Disappoints, Q2 Earnings Mixed Ahead of Bell: XOM, CVX, UPS, ABBV, BCS
Mark Vickery - Zacks Investment Research - Fri Jul 29, 8:55AM CDT
Both GDP results and Exxon's (XOM) earnings for Q2 were below expectations. Who outperformed the consensus before the bell Friday?
BCS: 9.13 (-0.18), XOM: 88.57 (+1.15), ABBV: 64.61 (+0.49), CVX: 102.43 (+1.50), UPS: 109.50 (-0.09)
AbbVie (ABBV) Tops 2Q Earnings & Revenue Estimates
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 7:58AM CDT
AbbVie (ABBV) surpassed expectations in Q2 and raised its outlook for the year.
ABBV: 64.61 (+0.49)
AbbVie Reports Second-Quarter 2016 Financial Results
PR Newswire - Fri Jul 29, 6:38AM CDT
AbbVie (NYSE:ABBV) announced financial results for the second quarter ended June 30, 2016.
ABBV: 64.61 (+0.49)
AbbVie Announces Initiation of Phase 3 Study of Venetoclax in Patients with Relapsed or Refractory Multiple Myeloma
PR Newswire - Thu Jul 28, 4:30PM CDT
AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced the initiation of a Phase 3 clinical trial to study the safety and efficacy of venetoclax in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma who are considered sensitive or naïve to proteasome inhibitors and have received one to three prior lines of therapy. The combination of venetoclax, bortezomib and dexamethasone will be compared to treatment with bortezomib, dexamethasone and placebo.1 Bortezomib, a proteasome inhibitor, and dexamethasone, a corticosteroid, are both common therapies used to treat symptomatic multiple myeloma.3
ABBV: 64.61 (+0.49)
The Zacks Analyst Blog Highlights: Biogen, Gilead, AbbVie, Amgen and Celgene
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 8:30AM CDT
The Zacks Analyst Blog Highlights: Biogen, Gilead, AbbVie, Amgen and Celgene
BIIB: 310.67 (-2.92), GILD: 77.88 (+0.99), AMGN: 170.84 (+1.07), ABBV: 64.61 (+0.49), CELG: 106.71 (+1.22)
2 Large Cap Drug Stocks to Watch for Earnings: ABBV & MRK
Arpita Dutt - Zacks Investment Research - Thu Jul 28, 5:47AM CDT
Two major large cap drug stocks, AbbVie (ABBV) and Merck (MRK) will be reporting second quarter results tomorrow.
BIIB: 310.67 (-2.92), JNJ: 119.75 (+0.43), GILD: 77.88 (+0.99), MRK: 63.24 (+0.26), AMGN: 170.84 (+1.07), ABBV: 64.61 (+0.49)
Biotech Stock Roundup: Biogen Q2 Results Impress, Gilead HCV Franchise Under Pressure
Arpita Dutt - Zacks Investment Research - Wed Jul 27, 2:25PM CDT
With the second quarter earnings season in full swing, several biotech companies including Amgen (AMGN) will be reporting this week.
BIIB: 310.67 (-2.92), VRTX: 95.78 (+0.67), GILD: 77.88 (+0.99), ALXN: 125.85 (+2.18), AMGN: 170.84 (+1.07), ABBV: 64.61 (+0.49), CELG: 106.71 (+1.22)
(0)
(0)Scroll down for more posts ▼